The management of patients with giant cell arteritis (GCA), the most common vasculitis in adults, has undergone significant transformation over the past decade [1]. This shift has been primarily driven by two key advancements: the expanded use of imaging for diagnosis and the introduction of novel therapeutic agents [2]. Before the widespread adoption of imaging techniques, the diagnosis of GCA largely relied on the presence of suggestive symptoms within a hyperinflammatory context, with histological confirmation requested only in selected cases.
